Subscription
Advanced Search
Share
Current Issue
Journal Information
Back to article

Statistics

Follow this link to access the full text of the article

Correspondence
No evidence for cardiotoxicity of miltefosine
Thomas P.C. Dorloa,b,
Corresponding author
thomasdorlo@gmail.com

Corresponding author.
a Department of Pharmacy & Pharmacology, Antoni van Leeuwenhoek Hospital/Netherlands Cancer Institute, Amsterdam, The Netherlands
b Department of Pharmacy, Uppsala University, Uppsala, Sweden
Read
2580
Times
was read the article
1123
Total PDF
1457
Total HTML
Share statistics
Article information
ISSN: 03650596
Original language: English
DOI:10.1016/j.abd.2022.03.002
The statistics are updated each day
Year/Month Html Pdf Total
2024 April 50 45 95
2024 March 90 55 145
2024 February 111 75 186
2024 January 107 39 146
2023 December 58 47 105
2023 November 69 102 171
2023 October 59 65 124
2023 September 68 72 140
2023 August 49 28 77
2023 July 44 21 65
2023 June 39 33 72
2023 May 37 18 55
2023 April 37 18 55
2023 March 43 41 84
2023 February 33 32 65
2023 January 41 34 75
2022 December 37 28 65
2022 November 70 48 118
2022 October 133 55 188
2022 September 57 73 130
2022 August 65 59 124
2022 July 114 74 188
2022 June 46 61 107
Show all

Follow this link to access the full text of the article

Subscribe to our newsletter

Bernardo Gontijo Award
Read More
Special content about COVID-19
Publish in
Anais Brasileiros de Dermatologia
Idiomas
Anais Brasileiros de Dermatologia
en pt
Cookies policy Política de cookies
To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here. Utilizamos cookies próprios e de terceiros para melhorar nossos serviços e mostrar publicidade relacionada às suas preferências, analisando seus hábitos de navegação. Se continuar a navegar, consideramos que aceita o seu uso. Você pode alterar a configuração ou obter mais informações aqui.